One growth stock I’d buy alongside this Neil Woodford favourite

Neil Woodford has an eye for top growth shares, and here’s one he might have missed.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

I was bullish about Spire Healthcare (LSE: SPI) when I examined the company last year, but since then the share price has fallen by 30% to 221p.

That was largely due to a profit warning in September, released along with first-half results. The results themselves weren’t bad, but early revenue growth at the independent hospital group had been driven by NHS referrals, and those were slowing.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

There’s a drop in EPS of 23% expected for the year just ended in December 2017, with results due on 2 March. January’s pre-close update confirmed previous guidance, and told us to expect revenue between £929m and £932m, with underlying EBITDA in the range of £149m to £151m.

Net debt stood at around £465m at 31 December, which is a little over three times the mid-point EBITDA estimate. I generally prefer that multiple to come in at around 2.5 times or less, but for a company that’s still a small fish in a big pond with potentially plenty of room to grow, I’m not too disturbed.

Growth opportunities

Spire only floated in 2014, and I expect new growth companies to go through early periods of volatility before their genuine potential settles down. And I’m encouraged by current forecasts.

Though pared back a little from earlier predictions, mooted EPS growth of 7% for 2018 and 11% for next year would drop the P/E to around 12. The modest dividend (currently set to yield 1.6%) is very well covered, and should soon ramp up.

Despite the recent fall, I see Spire Healthcare as having attractive long-term prospects.

Gene Therapy

I was a bit more fortunate in my upbeat stance on Oxford Biomedica (LSE: OXB) last March, and the share price has doubled since I gave it the nod. Priced at 11.5p as I write, the shares don’t yet command anything in the way of P/E valuations as there’s been no profit yet.

The 2017 year is expected to have brought in a pre-tax loss of around £11.6m, but that looks set to change with only a £6m loss forecast for 2018 and a tiny profit by 2019.

The “leading gene and cell therapy group” is in a very exciting area of medical research which is really only in its infancy. It’s risky trying to guess which companies will come to dominate the field, but there are so many potential treatments out there that there must be scope for many competitors

Important deal

Thursday’s news boosted Oxford Biomedica’s prospects, with the firm announcing “a major new collaboration & licence agreement with Bioverativ Inc. for the development and manufacturing of lentiviral vectors to treat haemophilia.

Bioverativ will gain access to Oxford’s LentiVector and manufacturing technologies, in a deal which is worth a $5m upfront payment coupled with “various milestone payments, potentially worth in excess of $100m” and royalties. I wonder if those Oxford Biomedica forecasts will be upgraded now?

I see Oxford Biomedica as a ‘picks and shovels’ operator in the gene and cell therapy business, offering technology that can be used for a variety of genetic therapies. Whichever treatments are eventually successful, companies which offer the development platforms should do well.

The market response has been a 7.5% share price rise (at the time of writing), but the full potential of this latest development might not have been fully understood. Oxford Biomedica looks a strong long-term buy to me.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Black father holding daughter in a field of cows
Investing Articles

Could my Stocks and Shares ISA generate £30,000 a year?

Over 2m UK citizens make some use of a Stocks and Shares ISA every year. Our writer considers if it’s…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

4 dividend stocks that can help me fight inflation!

I'm looking at dividend stocks to help my portfolio grow and overcome the impact of high inflation. Here are the…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

2 bargain UK shares trading at less than book value

Book value is a great way to value a stock. These UK shares are trading at a price-to-book ratio of…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

A FTSE AIM stock I’d add to my Stocks & Shares ISA in July

Henry Adefope highlights a FTSE AIM stock he believes could generate significant upside for his portfolio if he buys this…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

I’m following Warren Buffett and buying cheap dividend shares to build my wealth

I think this cheap dividend stock exhibits similar qualities to the companies Warren Buffett has in his investment portfolio.

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

2 cheap FTSE 100 shares I’m buying during the dip!

Andrew Woods explains that low P/E ratios and profitable businesses attract him to these two FTSE 100 shares.

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Down 45% in a year, is now the time to buy Scottish Mortgage shares?

Jon Smith explains why Scottish Mortgage shares appear to him to be good value given their post-pandemic fall.

Read more »

Tabletop model of a bear sat on desk in front of monitors showing stock charts
Investing Articles

3 reasons why the stock market is falling today

Jon Smith explains several factors that are contributing to the stock market falling today, and his thoughts on them.

Read more »